LYCA insider buying and SEC filings, explained
Lycia Therapeutics, Inc. · CIK 1806540
Tracked: Forms 3/4/5, 8-K, NT · All filings on sec.gov
Insider activity in the last 12 months
Bought
$38.3M
Insiders who bought
1
Sold (not marked 10b5-1)
$0
Planned sales (10b5-1)
$0
Insider purchases and sales, last 12 months
| Traded | Type | What was filed | Source |
|---|---|---|---|
| Oct 28–30, 2026 | Purchase (code P) | Bong Y Koh (10% owner) bought 25,004 shares indirectly between Oct 28 and Oct 30 at about $25.78 ($645K), reported as a purchase (code P). Indirect holdings up <1% to 6,850,237 shares. Not marked as a 10b5-1 plan trade. Filed jointly with 8 other reporting owners. | SEC filing Filed Oct 30, 2026, 7:25 PM ET |
| Oct 23–27, 2026 | Purchase (code P) | Bong Y Koh (10% owner) bought 2,045,440 shares indirectly between Oct 23 and Oct 27 at about $18.41 ($37.7M), reported as a purchase (code P). Indirect holdings up 43% to 6,825,233 shares. Not marked as a 10b5-1 plan trade. Filed jointly with 8 other reporting owners. | SEC filing Filed Oct 27, 2026, 6:38 PM ET |
10 routine transactions (such as grants, option exercises or tax withholding) are not listed.
Cluster buys
No cluster buys in the last 12 months.
Red flags
No red flags in the last 12 months.
Key events
No key events in the last 12 months.
8-K filings, last 12 months
No 8-K filings in the last 12 months.
Red flags are objective triggers only: the item or form filed, never an opinion.
Follow LYCA in the Insider Ledger app
Get the appA plain-English brief of insider purchases, 8-Ks and red flags at the companies you pick. No account needed.